Gareth Gerrard

Assessment of <i>BCR-ABL1</i> Transcript Levels at 3 Months Is the Only Requirement for Predicting Outcome for Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors

David Marín, Amr R. Ibrahim, Claire Lucas et al. · Journal of Clinical Oncology · 2011 · 474 citations · Full text

UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia

Adele K. Fielding, Jacob M. Rowe, Georgina Buck et al. · Blood · 2013 · 365 citations · Full text

Regulation of myeloid leukaemia by the cell-fate determinant Musashi

Takahiro Ito, Hyog Young Kwon, Bryan Zimdahl et al. · Nature · 2010 · 364 citations · Full text

Hematological Malignancy, Mixed-phenotype Acute Leukemia, Cell-fate Determinant Musashi +3

Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy

Amr R. Ibrahim, Lina Eliasson, Jane F. Apperley et al. · Blood · 2011 · 314 citations · Full text

Minimal residual disease is a significant predictor of treatment failure in non T‐lineage adult acute lymphoblastic leukaemia: final results of the international trial UKALL XII/ECOG2993

Bella Patel, Lena Rai, Georgina Buck et al. · British Journal of Haematology · 2009 · 151 citations

Mrd Positivity, Mixed-phenotype Acute Leukemia, Immunology +17